Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | WNT1 | P04628 | 2/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.30 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.30 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.30 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.30 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120609 | 1.00 | CNR2 (0.40) | CNR2DYRK1AGSK3BWNT1HSP90AA1 | |
| SCHEMBL4113697 | 0.91 | CNR2 (0.38) | CNR2DYRK1AGSK3BWNT1HSP90AA1 | |
| SCHEMBL4113703 | 0.91 | CNR2 (0.38) | CNR2DYRK1AGSK3BWNT1HSP90AA1 | |
| SCHEMBL4113665 | 0.88 | CNR2 (0.41) | CNR2ACKR3GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL4113668 | 0.88 | CNR2 (0.41) | CNR2ACKR3GUCY1B2GUCY1A2GUCY1A1 | |
| SCHEMBL1174239 | 0.86 | CNR2 (0.45) | CNR2DYRK1AGSK3BWNT1 | |
| SCHEMBL1174243 | 0.86 | CNR2 (0.45) | CNR2DYRK1AGSK3BWNT1 | |
| SCHEMBL4111019 | 0.86 | CNR2 (0.38) | CNR2DYRK1AGSK3B | |
| SCHEMBL4128374 | 0.86 | CNR2 (0.36) | CNR2 | |
| SCHEMBL4128376 | 0.86 | CNR2 (0.36) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431565-B2 | Substituted imidazoheterocycles | CARA THERAPEUTICS, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CARA THERAPEUTICS, INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149450-A1 | SUBSTITUTED IMIDAZOHETEROCYCLES | CNR1, CNR2, TRPV1 | CNR2 2/4885DYRK1A 1807/4885GSK3B 3020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.